secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2023-09-12T23:59:59+00:00
Accession:  0001193125-23-233500
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Viridian Therapeutics CFO Kristian Humer resigns; Seth Harmon appointed principal financial officer
--------------------------------------------------------------------------------

- Kristian Humer, CFO and CBO, resigns effective Sept 12, 2023; eligible for severance under existing agreement.
- Seth Harmon, SVP of Finance (joined May 2023), assumes role of principal financial and accounting officer.
- Harmon's base salary increased to $410,000; entitled to 12-month severance upon involuntary termination.
- Harmon previously CFO of BioNTech US subsidiary and held finance roles at Neon Therapeutics and Merrimack.
- Harmon is a CPA with prior experience at Ernst & Young.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312523233500/0001193125-23-233500-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312523233500/d638217d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-233500

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer